Catalyst Pharmaceuticals Stock Investor Sentiment
| CPRX Stock | USD 21.03 0.42 1.96% |
Slightly above 58% of Catalyst Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Catalyst Pharmaceuticals suggests that many traders are alarmed. Catalyst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Catalyst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 42
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Catalyst Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Catalyst Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Catalyst Historical Sentiment
Although Catalyst Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Catalyst, such as negative comments on social media and news outlets, may cause fear in the market and push Catalyst Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Catalyst.
Catalyst Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Catalyst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Catalyst Pharmaceuticals Historical Investor Sentiment
Investor biases related to Catalyst Pharmaceuticals' public news can be used to forecast risks associated with an investment in Catalyst. The trend in average sentiment can be used to explain how an investor holding Catalyst can time the market purely based on public headlines and social activities around Catalyst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Catalyst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Catalyst Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Catalyst Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Catalyst Pharmaceuticals.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Catalyst Pharmaceuticals' Stock prices. Below is the latest headlines and news related to Catalyst Pharmaceuticals Stock. Current markets are slightly bullish. About 58% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. This information is accessible both publicly - through Catalyst Pharmaceuticals' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Catalyst-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.
Catalyst Largest EPS Surprises
Earnings surprises can significantly impact Catalyst Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-09 | 2021-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-11-09 | 2020-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2020-05-11 | 2020-03-31 | 0.09 | 0.1 | 0.01 | 11 | ||
2018-11-07 | 2018-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2018-08-07 | 2018-06-30 | -0.07 | -0.06 | 0.01 | 14 | ||
2017-08-09 | 2017-06-30 | -0.06 | -0.05 | 0.01 | 16 |
There is far too much social signal, news, headlines, and media speculation about Catalyst Pharmaceuticals that are available to investors today. This information is accessible both publicly - through Catalyst Pharmaceuticals' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Catalyst-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Catalyst Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Catalyst Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Catalyst Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Catalyst Pharmaceuticals alpha.
Catalyst Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 44000 shares by Ingenito Gary of Catalyst Pharmaceuticals at 23.63 subject to Rule 16b-3 | 05/14/2025 |
2 | Disposition of 200000 shares by Ingenito Gary of Catalyst Pharmaceuticals at 23.68 subject to Rule 16b-3 | 05/15/2025 |
3 | Disposition of 14000 shares by Miller Steve of Catalyst Pharmaceuticals subject to Rule 16b-3 | 05/19/2025 |
4 | Why Catalyst Pharmaceutical is a Top Growth Stock for the Long-Term | 06/03/2025 |
5 | Disposition of 171748 shares by Patrick McEnany of Catalyst Pharmaceuticals at 26.11 subject to Rule 16b-3 | 06/09/2025 |
6 | Disposition of 1600 shares by Preethi Sundaram of Catalyst Pharmaceuticals at 26.42 subject to Rule 16b-3 | 06/11/2025 |
7 | Preethi Sundaram Implements A Sell Strategy Offloads 103K In Catalyst Pharmaceuticals Stock | 06/13/2025 |
8 | Heres Why Catalyst Pharmaceutical is a Strong Value Stock | 06/18/2025 |
9 | CPRX vs. NBIX Which Stock Is the Better Value Option | 06/23/2025 |
10 | Post-Traumatic Stress Disorder Market Set to Expand Significantly During the Study Period with Pipeline Innovation and Unmet Needs DelveInsight | 06/26/2025 |
11 | Are Investors Undervaluing Catalyst Pharmaceuticals Right Now | 06/30/2025 |
12 | Stratos Wealth Advisors LLC Makes New 2.02 Million Investment in Catalyst Pharmaceuticals, Inc. | 07/09/2025 |
13 | Hohimer Wealth Management LLC Grows Position in Catalyst Pharmaceuticals, Inc. | 07/15/2025 |
14 | What drives Catalyst Pharmaceuticals Inc. stock price - Rapid capital growth - Jammu Links News | 07/18/2025 |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.